Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the Stifel Healthcare Conference. The company's management will engage in a fireside chat on November 19th at 3:35 pm ET in New York City, along with one-on-one investor meetings.
The fireside chat will be available via webcast, accessible through both a direct link and the Events and Presentations section of Fulcrum's website. A replay will remain available for at least 30 days after the presentation.
Fulcrum Therapeutics (Nasdaq: FULC), una società biofarmaceutica in fase clinica specializzata nello sviluppo di piccole molecole per malattie genetiche rare, ha annunciato la sua partecipazione alla Stifel Healthcare Conference. La dirigenza dell'azienda parteciperà a una chiacchierata informale il 19 novembre alle 15:35 ET a New York, insieme a incontri individuali con gli investitori.
La chiacchierata informale sarà disponibile tramite webcast, accessibile sia tramite un link diretto sia attraverso la sezione Eventi e Presentazioni del sito web di Fulcrum. Una registrazione rimarrà disponibile per almeno 30 giorni dopo la presentazione.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en etapa clínica especializada en el desarrollo de pequeñas moléculas para enfermedades genéticas raras, ha anunciado su participación en la Stifel Healthcare Conference. La dirección de la empresa participará en una charla informal el 19 de noviembre a las 3:35 pm ET en Nueva York, junto con reuniones individuales con inversores.
La charla informal estará disponible a través de un webcast, accesible tanto mediante un enlace directo como en la sección de Eventos y Presentaciones del sitio web de Fulcrum. Una repetición estará disponible por al menos 30 días después de la presentación.
Fulcrum Therapeutics (Nasdaq: FULC)는 희귀 유전 질병을 위한 소분자 개발에 전문화된 임상 단계 생명공학 회사로, Stifel Healthcare Conference에 참가한다고 발표했습니다. 회사 관리팀은 11월 19일 오후 3시 35분 ET에 뉴욕에서 진행되는 화로 대화에 참여할 예정이며, 개별 투자자와의 미팅도 진행됩니다.
화로 대화는 웹캐스트를 통해 제공되며, Fulcrum 웹사이트의 이벤트 및 발표 섹션에서도 접근할 수 있습니다. 발표 후 최소 30일 동안 재생이 가능합니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise bio-pharmaceutique en phase clinique spécialisée dans le développement de petites molécules pour les maladies génétiques rares, a annoncé sa participation à la Stifel Healthcare Conference. La direction de l'entreprise participera à une discussion informelle le 19 novembre à 15h35 ET à New York, ainsi qu'à des réunions individuelles avec des investisseurs.
La discussion informelle sera disponible via une retransmission en direct, accessible à la fois par un lien direct et via la section Événements et Présentations du site web de Fulcrum. Un enregistrement sera disponible pendant au moins 30 jours après la présentation.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung kleiner Moleküle für seltene genetische Erkrankungen spezialisiert hat, hat seine Teilnahme an der Stifel Healthcare Conference angekündigt. Das Management des Unternehmens wird am 19. November um 15:35 Uhr ET in New York an einem Gespräch teilnehmen, zusammen mit individuellen Investorenmeetings.
Das Gespräch wird über ein Webcast verfügbar sein, der sowohl über einen direkten Link als auch über den Bereich Veranstaltungen und Präsentationen auf der Website von Fulcrum zugänglich ist. Eine Wiederholung wird für mindestens 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel Healthcare Conference in New York City on November 19th at 3:35 pm ET. Management will also participate in one-on-one investor meetings.
The webcast of the fireside chat will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the Stifel Healthcare Conference 2024?
How can investors access Fulcrum Therapeutics' (FULC) Stifel Conference presentation?
How long will the replay of Fulcrum Therapeutics' (FULC) Stifel presentation be available?
What type of presentation will Fulcrum Therapeutics (FULC) give at the Stifel Healthcare Conference?
